Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (796)	5/17/1999 4:54:00 PM
From: KLH	Read Replies (1) \| Respond to of 2344

SM, do you know what the low "ask" of the day was? I put in a token order to buy at 4 3/4 near the end of the day and got it. I don't have level two, but it seemed to me that they sold to me on the bid. Anyone? Karl

To: StockMiser who wrote (796)	5/17/1999 8:51:00 PM
From: Silver Knife	Read Replies (4) \| Respond to of 2344

May 17, 1999 Dow Jones Newswires DJ Biomira Stk Dn As Investors Sell On Theratope News By LORI MCLEOD Dow Jones Newswires TORONTO -- Biomira Inc.'s (BIOM) stock is off 12% on Nasdaq Monday as investors who bought the stock in anticipation of positive clinical results for Biomira's Theratope cancer vaccine sell on the news, Michael Jams, an analyst with Levesque Beaubien Geoffrion Inc., told Dow Jones. On Nasdaq, Biomira's stock is off 5/8 to 4 3/4 on about 2.1 million shares. In Toronto trading, Biomira's stock is off 0.80, or 10%, to 7.00, on about 818,000 shares. In a news release Saturday, Biomira said Theratope may increase survival and decrease relapse in ovarian and breast cancer patients following autologous stem cell transplant. While the news is good, it isn't unexpected, Jams said. He noted the stock had run up lately as investors anticipated the trial results would be positive. Biomira's shares opened at an intraday high of 8.70 in Toronto, and hit an intraday high of 6 3/16 on Nasdaq earlier Monday. Jams said the initial boost was likely due to buying by investors who don't follow Biomira's story closely and hadn't bought the stock in advance of the news. Biomira's stock may drift down a bit more, then stabilize until the company has another event to publicize, Jams said. Jams said his target price for Biomira is under review. -By Lori McLeod 416-306-2031; lori.mcleod@dowjones.ca